First-Line Chemotherapy Regimens for Unresectable Locally Advanced or Metastatic Biliary Tract Cancer
JAMA Network Open · 2026
DOI: 10.1001/jamanetworkopen.2026.6849 ↗Kurz gefasst
Netzwerk-Metaanalyse in der Zeitschrift JAMA Network Open, 2026. Verfasst von Abdulaziz Elemosho und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus. Hauptthemen laut MEDLINE: Biliary Tract Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Importance Biliary tract cancers (BTCs) are aggressive malignant neoplasms with a dismal prognosis. Recent advancements, including immunotherapy and targeted therapies, have expanded therapeutic options, yet head-to-head comparisons between regimens remain limited.
Objective
To conduct a comprehensive network meta-analyses (NMA) to include latest advances in BTC therapy to guide clinical practice. Data Sources PubMed, Embase, and Cochrane Central were searched for randomized clinical trials (RCT) from 2000 to 2024, with manual updates through August 2025 and conference abstracts and ClinicalTrials.gov screened. Study Selection Phase 2 to 3 RCTs of unresectable, locally advanced, or metastatic BTC reporting progression-free survival (PFS) or overall survival (OS) were eligible. Data Extraction and Synthesis The Preferred Reporting Items for Systematic Reviews and Meta-Analyses reporting guideline was followed. Two reviewers independently extracted data, resolving discrepancies with a third. Data were pooled with a fixed-effect model. Main Outcomes and Measures Primary outcomes were PFS and OS; secondary outcomes included objective response rate (ORR) and grade 3 to 4 adverse events.
Results
This systematic review and bayesian NMA synthesized data from 33 RCTs involving 7303 patients (median [IQR] age, 64 [63-65] years; 3704 [51.5%] male). Compared with gemcitabine plus cisplatin (GC), GC plus sintilimab plus anlotinib (hazard ratio [HR], 0.47; 95% CI, 0.28-0.80), GC plus S-1 (HR, 0.75; 95% CI, 0.59-0.97), and GC plus durvalumab (HR, 0.80; 95% CI, 0.66-0.97) were associated with highest PFS benefits. Capecitabine plus oxaliplatin (HR, 0.64; 95% CI, 0.44-0.92), GC plus durvalumab (HR, 0.71; 95% CI, 0.61-0.84), and gemcitabine plus oxaliplatin (GO) (HR, 0.78; 95% CI, 0.63-0.96) were associated with improved OS. ORR was highest with GC plus S-1 (odds ratio [OR], 4.13; 95% CI, 2.20-7.70), GC plus cediranib (OR, 3.20; 95% CI, 1.40-7.20), and GC plus durvalumab (OR, 1.60; 95% CI, 1.10-2.28) compared with GC. Toxicity profiles showed no significant hematological differences between regimens, but nonhematological risks varied. Overall, GC plus durvalumab, GC plus S-1, GO plus panitumumab, and GO plus cetuximab showed the greatest consistency in the surface under the cumulative ranking curve value for PFS, OS, ORR, and safety. Conclusions and relevance This NMA establishes GC plus durvalumab and GC plus S-1 as potential leading first-line options for advanced BTC due to a consistent clear benefit in PFS, OS, ORR, and safety. This study also establishes that GC remains among the top regimens, as most other therapy lacked a clear superior benefit or were associated with worse PFS or OS compared with GC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Surgery, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus.
Zitieren
APA
Elemosho, A., Blair, A. B., Angez, M., Chatzipanagiotou, O. P., Mevawalla, A., Alizai, Q., Yuza, K., & Pawlik, T. M. (2026). First-Line Chemotherapy Regimens for Unresectable Locally Advanced or Metastatic Biliary Tract Cancer. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2026.6849
Vancouver
Elemosho A, Blair AB, Angez M, Chatzipanagiotou OP, Mevawalla A, Alizai Q, et al. First-Line Chemotherapy Regimens for Unresectable Locally Advanced or Metastatic Biliary Tract Cancer. JAMA Network Open. 2026. doi:10.1001/jamanetworkopen.2026.6849
BibTeX
@article{Elemosho2026,
author = {Elemosho, Abdulaziz and Blair, Alex B and Angez, Meher and Chatzipanagiotou, Odysseas P and Mevawalla, Areesh and Alizai, Qaidar and Yuza, Kizuki and Pawlik, Timothy M},
title = {First-Line Chemotherapy Regimens for Unresectable Locally Advanced or Metastatic Biliary Tract Cancer},
journal = {JAMA Network Open},
year = {2026},
doi = {10.1001/jamanetworkopen.2026.6849}
}
EUVIMED